Unitaid has issued a call for proposals to fund innovative projects that would combat the drug-resistant strains of tuberculosis, and has announced progress in development of a new anti-malaria insecticide against mosquitoes. Continue reading ->
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading ->
The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading ->
Historicamente, o Brasil se encontra na vanguarda dos países em desenvolvimento, pressionando por um regime de propriedade intelectual (PI) mais equilibrado. Continue reading ->
The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading ->
The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading ->
The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading ->
The European Commission today issued an outline of a European approach on artificial intelligence to "boost investment and set ethical guidelines." The aim is to have a coordinated plan with member states by year's end. Continue reading ->
The Medicines Patent Pool announced today that it has appointed Charles Gore as new executive director. Gore is founder and former president of the World Hepatitis Alliance. Continue reading ->
Prof. Carlos Correa of Argentina, an influential academic whose analyses of patents and medicines access have informed debates and challenged the status quo for decades, has been named the next executive director of the South Centre. He will take over for Martin Khor, who will be retiring after nine years at the helm. Separately, former South African President Thabo Mbeki was named chair of the Board. Continue reading ->